<DOC>
	<DOCNO>NCT00731081</DOCNO>
	<brief_summary>To describe severe late onset patient pompe disease receive Myozyme®</brief_summary>
	<brief_title>Study About Evolution Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction Receiving Myozyme®</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>Male Female ≥ 18 year age ; The patient and/or patient 's legal representative give informed consent write study procedure initiate ; Pompe disease confirm documented deficit endogenous acid alphaglucosidase ( GAA ) activity ; A severe form disease define follow : . Moderate severe limb girdle muscle weakness require help walk around ( stick , crutch , walk frame wheelchair ) ; b . Symptoms diaphragmatic dysfunction define least 2 3 follow criterion : orthopnea , vital capacity &lt; 50 % , paradoxical respiration detect measurement transdiaphragmatic pressure ; c. Use invasive ventilation ( defined need tracheotomy ) noninvasive ventilation ( defined utilization assist ventilation use nasal facial mask ) day night prescribe ≥ 12 hours/day ; Treated ≥6 month Myozyme ; Followedup reference center accord CETP recommendation . The patient present major congenital anomaly ; The patient present clinically important organic disease ( except symptom relate Pompe disease ) cardiovascular , hepatic , pulmonary , neurological renal disease medical condition , serious disease particular circumstance investigator 's opinion , preclude patient 's participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>